Clinical trials
High Risk Prostate Carcinoma clinical trials
Below are recruiting high risk prostate carcinoma clinical trials, each written for real people, not researchers. We’re tracking 124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05410730RecruitingPhase 1/Phase 2
Early bladder cancer study using new drugs and BCG
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT05861050RecruitingPhase 1/Phase 2
Study of 4-drug treatment for newly diagnosed high-risk mantle cell lymphoma
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
Duarte, CaliforniaAges 18–80 - NCT04525989Recruiting
Short-course proton vs photon radiation before rectal surgery
This study compares two types of pre-surgery radiation—protons versus standard photons—in people with high-risk rectal cancer. The goal is to shrink and control the tumor while safely getting you ready for surgery, and to see which approach works better.
Stockholm, SolnaAges 18 years+ - NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Miami, FloridaAges 18 years+ - NCT05943379RecruitingPhase 2
RC48 antibody plus gemcitabine for high-risk bladder cancer
This Phase 2 study tests RC48, an antibody-based drug, combined with gemcitabine to treat high-risk, non-muscle invasive bladder cancer that has not responded well to BCG or cannot receive BCG. It may help shrink tumors and reduce the chance of the cancer coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06037980RecruitingPhase 2/Phase 3
Chemotherapy before surgery for high-risk bile duct cancer
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
AnconaAges 18–75 - NCT06287541Recruiting
Do you need a second bladder surgery after a negative urine test?
This study looks at whether a second bladder surgery is still needed for people with high-risk bladder cancer who had a negative urine test after their first surgery.
Nanjing, JiangsuAges 18 years+ - NCT06319196RecruitingPhase 2
Clearing melanoma with immunotherapy after surgery
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Toronto, OntarioAges 18 years+ - NCT06397313RecruitingPhase 2
New drug for myelofibrosis after JAK inhibitor failure
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
BolognaAges 18 years+ - NCT06407947RecruitingEarly Phase 1
CT071 for high-risk newly diagnosed multiple myeloma
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06482684RecruitingPhase 2
CAR-T cell therapy for new, high-risk mantle cell lymphoma
This study tests a type of immunotherapy called CAR-T cells (modified immune cells) for people with untreated, high-risk mantle cell lymphoma. It aims to see if this therapy can help control the disease early on.
MainzAges 18–75 - NCT06483906RecruitingPhase 2
Study of a drug combo and stem cell transplant for high-risk AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06509945Recruiting
Donor stem cell transplant for high-risk T-cell lymphoma
This trial tests giving a donor stem cell transplant (called allo-PBSCT) as the first treatment after chemotherapy for people with high-risk peripheral T-cell lymphoma. It may help prevent the lymphoma from coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06558981RecruitingPhase 3
Radiation therapy after thyroid surgery for high-risk cancer
This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.
ShanghaiAges 14–80 - NCT06696794RecruitingPhase 3
Testing mitomycin before surgery for high-risk bladder cancer
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Wuhan, HubeiAges 18–75 - NCT06762769RecruitingPhase 2
Isatuximab and iberdomide for high-risk smoldering myeloma
This trial is testing a combination of two drugs, isatuximab and iberdomide, to help people with high-risk smoldering myeloma avoid progressing to active multiple myeloma. It aims to see if this immunotherapy approach can delay or prevent the need for stronger treatments.
LondonAges 18 years+ - NCT06932757RecruitingPhase 2
Quisinostat after treatment for high-risk uveal melanoma
This trial tests whether taking quisinostat pills after standard treatment can lower the chance of uveal melanoma coming back in people whose original tumor had high-risk features. It is for patients who have finished their eye treatment (surgery or radiation) within the past 6 months and have no signs that the cancer has spread.
Miami, FloridaAges 19 years+ - NCT06977711RecruitingPhase 1
Testing a new drug combo for high-risk DLBCL
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
San Antonio, TexasAges 18 years+ - NCT07036731Recruiting
Urine test study for second bladder surgery
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
Nanjing, JiangsuAges 18–80 - NCT07049848RecruitingPhase 2
Study of atezolizumab with chemo and radiation for high-risk sarcoma
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
Houston, TexasAges 18 years+ - NCT01898039RecruitingPhase 1/Phase 2
Vaccine study for certain melanoma patients with specific blood markers
This trial tests a modified vaccine to help the immune system recognize melanoma. It is mainly for people with melanoma at higher risk or certain stages, and who have specific inherited tissue markers on blood testing.
JerusalemAges Any age - NCT07474103Recruiting
Chemo, radiation, and immunotherapy for high-risk rectal cancer
This trial tests a treatment plan that combines chemotherapy, radiation, and an immunotherapy drug before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes.
WuhanAges 18–75
Hear when a new High Risk Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk prostate carcinoma?
- Yes. Clin2 currently lists 124 recruiting high risk prostate carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk prostate carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk prostate carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.